More from oncology cro
More in Politics
Related Blogs
Archivo
compartir social
Best Details For Contract Research Organization Users
Publicado por oncology cro
Cuerpo
For patients with metastatic cancer, they may also be an additional treatment option when the cancer has become resistant to commonly used drugs.
Every cancer drug available in Canada has gone through a Contract Research Organization program that begins with laboratory testing and then progresses to phases involving human subjects. There are three phases of Contract Research Organization. Phases 1 and 2 normally include a smaller number of participants.
Researchers try to determine whether a new drug is effective and safe, what the possible side effects are, and the best dosage for that drug. Phase 3 trials can include up to 3,000 people and are typically offered in multiple cities across the country. At this stage, the drug has demonstrated Contract Research Organization benefits and researchers compare it to standard drugs to find out which provides the most benefit with acceptable side effects.
Researchers try to determine whether a new drug is effective and safe, what the possible side effects are, and the best dosage for that drug. Phase 3 trials can include up to 3,000 people and are typically offered in multiple cities across the country. At this stage, the drug has demonstrated Contract Research Organization benefits and researchers compare it to standard drugs to find out which provides the most benefit with acceptable side effects.
Currently, many of the Contract Research Organization underway in Canada are Phase 3. Trial participants are randomly separated into two groups: those receiving the study drug and those receiving another drug (known as control group). If you end up in the control group, you will either get the standard treatment or a placebo if there is no standard medicine.
In the case of Contract Research Organization for metastatic cancer, however, participants never receive a placebo so that they are never deprived of a treatment for their cancer. Neither the researchers nor the participants know which treatment is being administered so as to eliminate any possibility of bias in the conduct of the trial and its reporting.
Comentarios